CN Patent

CN117771239A — 乳腺癌的拉索昔芬治疗

Assigned to Duke University · Expires 2024-03-29 · 2y expired

What this patent protects

本公开提供了用有效量的拉索昔芬、其药学上可接受的盐或其前药治疗妇女的雌激素受体阳性(ER + )癌症的方法。本公开还包括对导致内分泌抗性的雌激素受体1(ESR1)基因突变的检测和对内分泌抗性ER + 癌症的治疗。

USPTO Abstract

本公开提供了用有效量的拉索昔芬、其药学上可接受的盐或其前药治疗妇女的雌激素受体阳性(ER + )癌症的方法。本公开还包括对导致内分泌抗性的雌激素受体1(ESR1)基因突变的检测和对内分泌抗性ER + 癌症的治疗。

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: CN117771239A
Jurisdiction: CN
Classification: —
Expires: 2024-03-29
Drug substance claim: No
Drug product claim: No
Assignee: Duke University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.